Neuroprotective Agents for ALS
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Scientists at many institutions are researching to find neuroprotective agents for ALS. While today's guests research focuses on other neurological diseases, he recently wrote a commentary to a published neurology article about ALS research suggesting that the properties of a drug, Taxol should also be considered in animal models researching ALS. In this segment, Dr. Mark Nolan Hill talks with Dr. William Burke about ALS and why Taxol may be a worthwhile drug to examine in animal models as a neuoroprotective agent for ALS.
Overview
Scientists at many institutions are researching to find neuroprotective agents for ALS. While today's guests research focuses on other neurological diseases, he recently wrote a commentary to a published neurology article about ALS research suggesting that the properties of a drug, Taxol should also be considered in animal models researching ALS. In this segment, Dr. Mark Nolan Hill talks with Dr. William Burke about ALS and why Taxol may be a worthwhile drug to examine in animal models as a neuoroprotective agent for ALS.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Updates From the 7th World Symposium Task Force
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
Partnering with Patients: Building Effective Communication and Support in HF Care
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?